Akèy › Kansè tete negatif triple › Pennsylvania › York
Etid klinik pou Kansè tete negatif triple nan York, PA
4 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote York (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- WellSpan York Cancer Center, York
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Ap rekriteFaz 3
- Cancer Care Associates Of York ( Site 9517), York
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Cancer Care Associates of York, York
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Ap rekriteEtid obsèvasyon
- Cancer Care Associates of York, York
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan York
- Kansè Poumon ki pa ti selil15 etid
- Kansè (tout kalite)8 etid
- Kansè nan tete8 etid
- Kansè poumon8 etid
- Karsinòm selil skuamèz tèt ak kou7 etid
- Kansè ovè6 etid
- Kansè pwostat5 etid
- Maladi atè koronè5 etid
- Kansè Ezofajyen4 etid
- Kansè kolorektal4 etid
- Kansè Endomèt4 etid
- Kansè kolon3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.